Report Detail

Pharma & Healthcare Global Human Recombinant Insulin Market Research Report 2021

  • RnM4238351
  • |
  • 19 February, 2021
  • |
  • Global
  • |
  • 121 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

1 Human Recombinant Insulin Market Overview

  • 1.1 Product Overview and Scope of Human Recombinant Insulin
  • 1.2 Human Recombinant Insulin Segment by Type
    • 1.2.1 Global Human Recombinant Insulin Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Rapid-Acting Human Insulin
    • 1.2.3 Regular (Short Acting) Insulin
    • 1.2.4 NPH (Intermediate Acting) Insulin
    • 1.2.5 Long-Acting Human Insulin
    • 1.2.6 Premixed Human Insulins Insulin
  • 1.3 Human Recombinant Insulin Segment by Application
    • 1.3.1 Human Recombinant Insulin Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospital
    • 1.3.3 Retail Pharmacy
    • 1.3.4 Online Pharmacies
    • 1.3.5 Other
  • 1.4 Global Human Recombinant Insulin Market Size Estimates and Forecasts
    • 1.4.1 Global Human Recombinant Insulin Revenue 2016-2027
    • 1.4.2 Global Human Recombinant Insulin Sales 2016-2027
    • 1.4.3 Human Recombinant Insulin Market Size by Region: 2016 Versus 2021 Versus 2027

2 Human Recombinant Insulin Market Competition by Manufacturers

  • 2.1 Global Human Recombinant Insulin Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Human Recombinant Insulin Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Human Recombinant Insulin Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Human Recombinant Insulin Manufacturing Sites, Area Served, Product Type
  • 2.5 Human Recombinant Insulin Market Competitive Situation and Trends
    • 2.5.1 Human Recombinant Insulin Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Human Recombinant Insulin Players Market Share by Revenue
    • 2.5.3 Global Human Recombinant Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Human Recombinant Insulin Retrospective Market Scenario by Region

  • 3.1 Global Human Recombinant Insulin Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Human Recombinant Insulin Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Human Recombinant Insulin Market Facts & Figures by Country
    • 3.3.1 North America Human Recombinant Insulin Sales by Country
    • 3.3.2 North America Human Recombinant Insulin Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Human Recombinant Insulin Market Facts & Figures by Country
    • 3.4.1 Europe Human Recombinant Insulin Sales by Country
    • 3.4.2 Europe Human Recombinant Insulin Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Human Recombinant Insulin Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Human Recombinant Insulin Sales by Region
    • 3.5.2 Asia Pacific Human Recombinant Insulin Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Human Recombinant Insulin Market Facts & Figures by Country
    • 3.6.1 Latin America Human Recombinant Insulin Sales by Country
    • 3.6.2 Latin America Human Recombinant Insulin Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Human Recombinant Insulin Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Human Recombinant Insulin Sales by Country
    • 3.7.2 Middle East and Africa Human Recombinant Insulin Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Human Recombinant Insulin Historic Market Analysis by Type

  • 4.1 Global Human Recombinant Insulin Sales Market Share by Type (2016-2021)
  • 4.2 Global Human Recombinant Insulin Revenue Market Share by Type (2016-2021)
  • 4.3 Global Human Recombinant Insulin Price by Type (2016-2021)

5 Global Human Recombinant Insulin Historic Market Analysis by Application

  • 5.1 Global Human Recombinant Insulin Sales Market Share by Application (2016-2021)
  • 5.2 Global Human Recombinant Insulin Revenue Market Share by Application (2016-2021)
  • 5.3 Global Human Recombinant Insulin Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Novo Nordisk
    • 6.1.1 Novo Nordisk Corporation Information
    • 6.1.2 Novo Nordisk Description and Business Overview
    • 6.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Novo Nordisk Product Portfolio
    • 6.1.5 Novo Nordisk Recent Developments/Updates
  • 6.2 Eli Lilly and Company
    • 6.2.1 Eli Lilly and Company Corporation Information
    • 6.2.2 Eli Lilly and Company Description and Business Overview
    • 6.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Eli Lilly and Company Product Portfolio
    • 6.2.5 Eli Lilly and Company Recent Developments/Updates
  • 6.3 Sanofi
    • 6.3.1 Sanofi Corporation Information
    • 6.3.2 Sanofi Description and Business Overview
    • 6.3.3 Sanofi Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Sanofi Product Portfolio
    • 6.3.5 Sanofi Recent Developments/Updates
  • 6.4 Julphar Gulf Pharmaceutical Industries
    • 6.4.1 Julphar Gulf Pharmaceutical Industries Corporation Information
    • 6.4.2 Julphar Gulf Pharmaceutical Industries Description and Business Overview
    • 6.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Julphar Gulf Pharmaceutical Industries Product Portfolio
    • 6.4.5 Julphar Gulf Pharmaceutical Industries Recent Developments/Updates
  • 6.5 Bioton
    • 6.5.1 Bioton Corporation Information
    • 6.5.2 Bioton Description and Business Overview
    • 6.5.3 Bioton Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Bioton Product Portfolio
    • 6.5.5 Bioton Recent Developments/Updates
  • 6.6 Gan & Lee Pharmaceuticals
    • 6.6.1 Gan & Lee Pharmaceuticals Corporation Information
    • 6.6.2 Gan & Lee Pharmaceuticals Description and Business Overview
    • 6.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Gan & Lee Pharmaceuticals Product Portfolio
    • 6.6.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
  • 6.7 Zhuhai United Laboratories
    • 6.6.1 Zhuhai United Laboratories Corporation Information
    • 6.6.2 Zhuhai United Laboratories Description and Business Overview
    • 6.6.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Zhuhai United Laboratories Product Portfolio
    • 6.7.5 Zhuhai United Laboratories Recent Developments/Updates
  • 6.8 Biocon
    • 6.8.1 Biocon Corporation Information
    • 6.8.2 Biocon Description and Business Overview
    • 6.8.3 Biocon Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Biocon Product Portfolio
    • 6.8.5 Biocon Recent Developments/Updates
  • 6.9 Wanbang Biopharmaceuticals
    • 6.9.1 Wanbang Biopharmaceuticals Corporation Information
    • 6.9.2 Wanbang Biopharmaceuticals Description and Business Overview
    • 6.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Wanbang Biopharmaceuticals Product Portfolio
    • 6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates
  • 6.10 Dongbao Enterprise Group
    • 6.10.1 Dongbao Enterprise Group Corporation Information
    • 6.10.2 Dongbao Enterprise Group Description and Business Overview
    • 6.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Dongbao Enterprise Group Product Portfolio
    • 6.10.5 Dongbao Enterprise Group Recent Developments/Updates
  • 6.11 PeproTech
    • 6.11.1 PeproTech Corporation Information
    • 6.11.2 PeproTech Human Recombinant Insulin Description and Business Overview
    • 6.11.3 PeproTech Human Recombinant Insulin Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 PeproTech Product Portfolio
    • 6.11.5 PeproTech Recent Developments/Updates

7 Human Recombinant Insulin Manufacturing Cost Analysis

  • 7.1 Human Recombinant Insulin Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Human Recombinant Insulin
  • 7.4 Human Recombinant Insulin Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Human Recombinant Insulin Distributors List
  • 8.3 Human Recombinant Insulin Customers

9 Human Recombinant Insulin Market Dynamics

  • 9.1 Human Recombinant Insulin Industry Trends
  • 9.2 Human Recombinant Insulin Growth Drivers
  • 9.3 Human Recombinant Insulin Market Challenges
  • 9.4 Human Recombinant Insulin Market Restraints

10 Global Market Forecast

  • 10.1 Human Recombinant Insulin Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Human Recombinant Insulin by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Human Recombinant Insulin by Type (2022-2027)
  • 10.2 Human Recombinant Insulin Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Human Recombinant Insulin by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Human Recombinant Insulin by Application (2022-2027)
  • 10.3 Human Recombinant Insulin Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Human Recombinant Insulin by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Human Recombinant Insulin by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Rapid-Acting Human Insulin
    Regular (Short Acting) Insulin
    NPH (Intermediate Acting) Insulin
    Long-Acting Human Insulin
    Premixed Human Insulins Insulin

    Segment by Application
    Hospital
    Retail Pharmacy
    Online Pharmacies
    Other

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    Novo Nordisk
    Eli Lilly and Company
    Sanofi
    Julphar Gulf Pharmaceutical Industries
    Bioton
    Gan & Lee Pharmaceuticals
    Zhuhai United Laboratories
    Biocon
    Wanbang Biopharmaceuticals
    Dongbao Enterprise Group
    PeproTech


    Summary:
    Get latest Market Research Reports on Human Recombinant Insulin. Industry analysis & Market Report on Human Recombinant Insulin is a syndicated market report, published as Global Human Recombinant Insulin Market Research Report 2021. It is complete Research Study and Industry Analysis of Human Recombinant Insulin market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $2,900.00
    $4,350.00
    $5,800.00
    2,108.94
    3,163.41
    4,217.88
    2,426.26
    3,639.39
    4,852.52
    316,900.40
    475,350.60
    633,800.80
    218,211.95
    327,317.93
    436,423.90
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report